Related Experiment Videos
Disposition of medroxyprogesterone acetate and drug metabolism activity
Abstract:
The role of drug-metabolizing enzyme activity on the disposition of medroxyprogesterone acetate (MPA) was investigated in male rats. The metabolizing enzyme system was induced by phenobarbital (PB) or inhibited by SKF 525A. Plasma concentrations of unmetabolized MPA and the amounts of MPA-related residues in various tissues were higher in the SKF 525A and slightly lower in the PB treated animals than in the controls. The disappearance of MPA-related substances from the lung, skeletal muscle and brain was slow, and in the lung there was even an increase in the amount of radioactivity in the PB and saline treated rats at 24 hr. Almost equal amounts of radioactivity were excreted in the urine and intestine in the control rats, while the induction of drug metabolism enhanced the excretion in the urine and its reduction enhanced elimination in the intestinal tract within 24 hours. The findings demonstrate that plasma and tissue levels of MPA and its elimination route are influenced by the drug metabolism activity.
Insights
Drug metabolism affects medroxyprogesterone acetate (MPA) levels and elimination in rats. Enzyme induction altered MPA excretion routes, while inhibition increased tissue drug residues.
Area of Science:
- Pharmacology
- Toxicology
- Drug Metabolism
Background:
- Medroxyprogesterone acetate (MPA) is a widely used progestin.
- Understanding MPA disposition is crucial for its therapeutic application and safety.
- Drug-metabolizing enzymes significantly influence xenobiotic pharmacokinetics.
Purpose of the Study:
- To investigate the impact of drug-metabolizing enzyme activity on medroxyprogesterone acetate (MPA) disposition in male rats.
- To elucidate how enzyme induction and inhibition affect MPA plasma concentrations, tissue distribution, and excretion pathways.
Main Methods:
- Male rats were treated with phenobarbital (PB) to induce drug metabolism or SKF 525A to inhibit it.
- Plasma concentrations of unmetabolized MPA and MPA-related residues in tissues were quantified.
- Radioactivity excretion via urine and feces was measured over 24 hours.
Main Results:
- SKF 525A treatment led to higher plasma MPA concentrations and tissue residues compared to controls.
- Phenobarbital treatment resulted in slightly lower plasma MPA levels.
- Elimination routes shifted: urine excretion increased with PB, while intestinal elimination was favored with SKF 525A.
Conclusions:
- Drug-metabolizing enzyme activity plays a significant role in modulating medroxyprogesterone acetate (MPA) plasma and tissue levels.
- Enzyme activity influences the primary route of MPA elimination, impacting its overall pharmacokinetic profile.